Edward Anders Kolb, MD

Physician - Moonlighter

Nemours Children's Hospital, Delaware 1600 Rockland Road Wilmington, DE 19803

Biography

E. Anders Kolb, MD is Director of the Nemours Center for Cancer and Blood Disorders, Wilmington, Delaware, and Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Kolb is a national leader in the Children's Oncology Group (COG), chairing its Myeloid Disease Committee from 2012-2022, and serving on its Scientific Council. In addition, Dr. Kolb is a member of the FDA Oncologic Drug Advisory Committee's Pediatric Subcommittee and the National Heart, Lung and Blood Institute Bone Marrow Transplant Clinical Trials Network Data and Safety Monitoring Board. Dr. Kolb has proudly served as Co-Chair of the Leukemia & Lymphoma Society PedAL initiative. PedAL is a master clinical trial that will test simultaneously multiple targeted therapies for children who face a relapse of their acute leukemia. The study will take place at more than 200 sites worldwide. Dr. Kolb is certified by the American Board of Pediatrics and its sub-board in pediatric hematology/oncology. He completed pediatric residency training at St. Christopher's Hospital for Children and fellowship training in hematology/oncology in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center. Among his clinical and research interests are bone marrow transplantation, acute myeloid leukemia (AML), and drug development for children with leukemias. Dr. Kolb, continually funded by the National Institute of Health, has published more than 170 scientific manuscripts. He serves as the Principal Investigator on the Nemours Children's Health System National Cancer Institute Community Oncology Research Program and the Nemours Sickle Cell Center of Biomedical Research Excellence. Under his leadership, Nemours has been consistently ranked among the top U.S. children's hospitals for pediatric oncology and hematology, exceeding national benchmarks for five-year cancer survival rates and bone marrow transplant survival rates.

Fellowship

  • Pediatric Hematology/Oncology - Memorial Sloan Kettering Cancer Center, 2002

Residency

  • Pediatrics - St. Christophers Hospital for Children, 1999

Education

  • M.D. - Thomas Jefferson University - Medical College, 1996

  • Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG; Cancers; (2021).

    View Full Publication
  • Protection against bovine respiratory syncytial virus in calves vaccinated with adjuvanted modified live vaccine administered in the face of maternal antibody; Vaccine; (2020).

    View Full Publication
  • Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report; Pediatric Blood and Cancer; (2020).

    View Full Publication
  • Phase I/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: A report from the children's oncology group; Journal of Clinical Oncology; (2020).

    View Full Publication
  • Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration; European Journal of Cancer; (2020).

    View Full Publication
  • Morphologic remission status is limited compared to DN flow cytometry: a Children's Oncology Group AAML0531 report; Blood Advances; (2020).

    View Full Publication
  • Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology; Molecular Therapy - Methods and Clinical Development; (2020).

    View Full Publication
  • Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium; Pediatric Hematology and Oncology; (2020).

    View Full Publication
  • Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium; Pediatric Blood and Cancer; (2020).

    View Full Publication
  • Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring; BMC Medical Genomics; (2020).

    View Full Publication
  • Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: A report from the Children's oncology group; Journal of Clinical Oncology; (2020).

    View Full Publication
  • Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium; Pediatric Blood and Cancer; (2020).

    View Full Publication
  • Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group; Haematologica; (2020).

    View Full Publication
  • Aggressive hematopoietic malignancy characterized by biallelic loss of SMARCB1; JCO Precision Oncology; (2020).

    View Full Publication
  • A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study; Biology of Blood and Marrow Transplantation; (2020).

    View Full Publication
  • Stability and change in family psychosocial risk over 6 months in pediatric cancer and its association with medical and psychosocial healthcare utilization; Pediatric Blood and Cancer; (2020).

    View Full Publication
  • Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples; Genomics and Informatics; (2020).

    View Full Publication
  • p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma; Scientific Reports; (2019).

    View Full Publication
  • Screening for Family Psychosocial Risk in Pediatric Hematopoietic Stem Cell Transplantation with the Psychosocial Assessment Tool; Biology of Blood and Marrow Transplantation; (2019).

    View Full Publication
  • Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy; Pediatric Blood and Cancer; (2019).

    View Full Publication
  • Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group; Cancer Medicine; (2019).

    View Full Publication
  • Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group; Pediatric Blood and Cancer; (2019).

    View Full Publication
  • A psychosocial clinical care pathway for pediatric hematopoietic stem cell transplantation; Pediatric Blood and Cancer; (2019).

    View Full Publication
  • Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group; Pediatric Blood and Cancer; (2019).

    View Full Publication
  • Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design; Cell Reports; (2019).

    View Full Publication
  • Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia; Leukemia; (2019).

    View Full Publication
  • Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials; Pediatric Blood and Cancer; (2019).

    View Full Publication
  • Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania; Journal of Molecular Diagnostics; (2019).

    View Full Publication
  • Bone marrow transplant and pediatric multiple myeloma; Pediatric Blood and Cancer; (2019).

    View Full Publication
  • A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group; Pediatric Blood and Cancer; (2019).

    View Full Publication
  • Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions (Nature Medicine, (2017), 24, 1, (103-112), 10.1038/nm.4439); Nature Medicine; (2019).

    View Full Publication
  • Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial; Cancer; (2018).

    View Full Publication
  • The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions; Nature Medicine; (2018).

    View Full Publication
  • Development of chemotherapy with cell-cycle inhibitors for adult and pediatric cancer therapy; Cancer Research; (2018).

    View Full Publication
  • Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States; Pediatric Blood and Cancer; (2018).

    View Full Publication
  • Cytotoxicity of zardaverine in embryonal rhabdomyosarcoma from a Costello syndrome patient; Frontiers in Oncology; (2017).

    View Full Publication
  • Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2017).

    View Full Publication
  • CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome; Molecular Therapy - Nucleic Acids; (2017).

    View Full Publication
  • Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia; Leukemia Research; (2017).

    View Full Publication
  • Down syndrome and AML: Where do we go from here?; Blood; (2017).

    View Full Publication
  • Disease characteristics and prognostic implications of cell-surface FLT3 receptor (CD135) expression in pediatric acute myeloid leukemia: A report from the Children's Oncology Group; Clinical Cancer Research; (2017).

    View Full Publication
  • The microtubule network and cell death are regulated by an miR-34a/stathmin 1/ßIIITubulin axis; Molecular Cancer Research; (2017).

    View Full Publication
  • Implementing the psychosocial standards in pediatric cancer: Current staffing and services available; Pediatric Blood and Cancer; (2017).

    View Full Publication
  • Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada; Pediatric Blood and Cancer; (2017).

    View Full Publication
  • MicroRNA expression-based model indicates event-free survival in pediatric acute myeloid leukemia; Journal of Clinical Oncology; (2017).

    View Full Publication
  • Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2017).

    View Full Publication
  • Recent advances of cell-cycle inhibitor therapies for pediatric cancer; Cancer Research; (2017).

    View Full Publication
  • Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma; Oncotarget; (2016).

    View Full Publication
  • Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2016).

    View Full Publication
  • Initial Testing (Stage 1) of MK-8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2016).

    View Full Publication
  • Generation of pediatric leukemia xenograft models in NSG-B2m mice: Comparison with NOD/SCID mice; Frontiers in Oncology; (2016).

    View Full Publication
  • Evaluation of alternative in vivo drug screening methodology: A single mouse analysis; Cancer Research; (2016).

    View Full Publication
  • CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML; Blood; (2016).

    View Full Publication
  • Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma; Pediatric Blood and Cancer; (2016).

    View Full Publication
  • Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program; Pediatric Blood and Cancer; (2016).

    View Full Publication
  • Vorinostat enhances cytotoxicity of SN-38 and temozolomide in ewing sarcoma cells and activates STAT3/AKT/MAPK pathways; PLoS ONE; (2015).

    View Full Publication
  • Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric Cancer Models in the Pediatric Preclinical Testing Program; Clinical Cancer Research; (2015).

    View Full Publication
  • Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane<sup>®</sup>) by the Pediatric Preclinical Testing Program (PPTP); Pediatric Blood and Cancer; (2015).

    View Full Publication
  • Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2015).

    View Full Publication
  • Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673; Pediatric Blood and Cancer; (2015).

    View Full Publication
  • Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2015).

    View Full Publication
  • Domestic pigs are susceptible to infection with influenza B viruses; Journal of Virology; (2015).

    View Full Publication
  • Collaborative efforts driving progress in pediatric acute myeloid leukemia; Journal of Clinical Oncology; (2015).

    View Full Publication
  • Challenges in converting Acute Myeloid Leukemia (AML) genomics into AML clinical trials; Journal of Clinical Oncology; (2015).

    View Full Publication
  • Disruption of Annexin II /p11 interaction suppresses leukemia cell binding, homing and engraftment, and sensitizes the leukemia cells to chemotherapy; PLoS ONE; (2015).

    View Full Publication
  • A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report; Pediatric Blood and Cancer; (2015).

    View Full Publication
  • Acute myeloid leukemia in children and adolescents: Identification of new molecular targets brings promise of new therapies; Hematology (United States); (2015).

    View Full Publication
  • Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

    View Full Publication
  • Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2014).

    View Full Publication
  • Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

    View Full Publication
  • Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

    View Full Publication
  • Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

    View Full Publication
  • Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

    View Full Publication
  • Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

    View Full Publication
  • Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma; PLoS ONE; (2014).

    View Full Publication
  • Oncolytic viruses for potential osteosarcoma therapy; Advances in Experimental Medicine and Biology; (2014).

    View Full Publication
  • Outcomes of Allogeneic Hematopoietic cell transplantation in patients with Dyskeratosis Congenita; Biology of Blood and Marrow Transplantation; (2013).

    View Full Publication
  • Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: Tumor models for cancer drug discovery; Expert Opinion on Drug Discovery; (2013).

    View Full Publication
  • Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

    View Full Publication
  • Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

    View Full Publication
  • Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

    View Full Publication
  • Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

    View Full Publication
  • Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

    View Full Publication
  • Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

    View Full Publication
  • BIRC5 expression is a poor prognostic marker in Ewing sarcoma; Pediatric Blood and Cancer; (2013).

    View Full Publication
  • A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma; Frontiers in Oncology; (2013).

    View Full Publication
  • Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Progress of oncolytic viruses in sarcomas; Expert Review of Anticancer Therapy; (2012).

    View Full Publication
  • Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

    View Full Publication
  • Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).

    View Full Publication
  • Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts; Cancer; (2011).

    View Full Publication
  • Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer; Cancer Chemotherapy and Pharmacology; (2011).

    View Full Publication
  • Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).

    View Full Publication
  • Initial testing of lenalidomide by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).

    View Full Publication
  • Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).

    View Full Publication
  • Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

    View Full Publication
  • Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

    View Full Publication
  • Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

    View Full Publication
  • Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

    View Full Publication
  • Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

    View Full Publication
  • Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

    View Full Publication
  • Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program; Molecular Cancer Therapeutics; (2010).

    View Full Publication
  • R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts; Pediatric Blood and Cancer; (2010).

    View Full Publication
  • Past, present and future of therapies in pediatric sarcomas; Future Oncology; (2010).

    View Full Publication
  • Moving towards non-invasive assessments of prognosis in osteosarcoma; Pediatric Blood and Cancer; (2010).

    View Full Publication
  • Intracranial hemorrhage in alloimmune thrombocytopenia: Stratified management to prevent recurrence in the subsequent affected fetus; American Journal of Obstetrics and Gynecology; (2010).

    View Full Publication
  • Initial testing of topotecan by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

    View Full Publication
  • Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP); Pediatric Blood and Cancer; (2010).

    View Full Publication
  • Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma; Cancer Chemotherapy and Pharmacology; (2009).

    View Full Publication
  • Initial testing of Aplidin by the pediatric pre-clinical testing program; Pediatric Blood and Cancer; (2009).

    View Full Publication
  • Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2009).

    View Full Publication
  • Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2009).

    View Full Publication
  • Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2009).

    View Full Publication
  • Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo; Clinical Cancer Research; (2009).

    View Full Publication
  • Development of IGF-IR inhibitors in pediatric sarcomas; Current Oncology Reports; (2009).

    View Full Publication
  • Initial testing of cisplatin by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

    View Full Publication
  • Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

    View Full Publication
  • Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

    View Full Publication
  • Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

    View Full Publication
  • Initial testing of dasatinib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

    View Full Publication
  • Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2008).

    View Full Publication
  • The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: A case report; Chemotherapy; (2008).

    View Full Publication
  • Successful outcome with tandem myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient with atypical teratoid/rhabdoid tumor of the central nervous system; Journal of Neuro-Oncology; (2008).

    View Full Publication
  • Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

    View Full Publication
  • The pediatric preclinical testing program: Description of models and early testing results; Pediatric Blood and Cancer; (2007).

    View Full Publication
  • The neuroradiological findings in a case of Revesz syndrome; Pediatric Radiology; (2007).

    View Full Publication
  • The folate receptor α is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate; Clinical Cancer Research; (2007).

    View Full Publication
  • Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma; Clinical Cancer Research; (2007).

    View Full Publication
  • Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia; Obstetrics and Gynecology; (2006).

    View Full Publication
  • Dickkopf 3 Inhibits Invasion and Motility of Saos-2 Osteosarcoma Cells by Modulating the Wnt-β-Catenin Pathway; Cancer Research; (2004).

    View Full Publication
  • Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma; Cancer; (2003).

    View Full Publication
  • Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults; Journal of Clinical Oncology; (2003).

    View Full Publication
  • Imatinib Mesylate in Philadelphia Chromosome-Positive Leukemia of Childhood; Cancer; (2003).

    View Full Publication
  • A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia; Leukemia; (2003).

    View Full Publication
  • Ecteinascidin-743 inhibits activated but not constitutive transcription; Cancer Research; (2002).

    View Full Publication
  • The prevalence of TB infection in a population of homeless persons in Philadelphia; Chest; (1996).

    View Full Publication